Boryung, Dongwha sign deal to sell antihypertensive drug

Published: 2012-12-03 06:58:00

Updated: 2012-12-03 06:58:00

Boryung Pharm said Thursday it established a strategic partnership with Dongwha Pharm to sell the new combination form of an antihypertensive drug (fimasartan plus diuretic) in Korea and overseas.

Boryung completed the phase III clinical trial for such combination drug in May.

Under the dea...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK